NNOX|EPS -$0.17 vs -$0.20 est (+15.0%)|Rev $3.7M|Net Loss $33.4MNano-X Imaging Ltd. reported a narrower-than-expected loss for the fourth quarter of 2025, posting a non-GAAP loss per share of $0.17 compared with Wall Street’s estimate of a $0.20 loss. The medical imaging technology company generated revenue of $3.7M for the quarter, up 24.0% from $3.0M in the same period last year, as it continues scaling deployment of its Nanox.ARC digital X-ray systems.
The company deployed 36 units during the quarter and operated 36 systems in deployment at quarter end. Bottom line showed a net loss of $11.2M as Nano-X invests in expanding its novel digital imaging platform designed to increase access to early detection medical imaging.
For the full year ahead, management expects revenue of $35.0M. The company’s technology aims to disrupt traditional medical imaging by offering lower-cost alternatives to conventional X-ray systems, though commercial traction remains in early stages as the Israeli firm works to establish its market presence and regulatory approvals across global markets.
Wall Street consensus stands at 6 buy, 1 hold, 0 sell, reflecting analyst optimism about the company’s long-term potential in democratizing medical imaging access despite continued quarterly losses. The medical device maker trades on NASDAQ under the ticker NNOX.
A detailed analysis of Nano-X Imaging Ltd.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.